Adicet Bio (FRA:1IJ) Research & Development: €80.62 Mil (TTM As of Mar. 2026)


FRA:1IJ Adicet Bio Inc FRA:1IJ
31 GF Score
Price €6.60
! 3 Warning Signs
View Full Analysis

What is Adicet Bio Research & Development?

Adicet Bio FRA:1IJ -5.04% 31 Research & Development is €80.62 Mil as of Mar. 2026. GuruFocus rates FRA:1IJ with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Adicet Bio's Research & Development for the three months ended in Mar. 2026 was €15.13 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €80.62 Mil.

Adicet Bio  (FRA:1IJ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Adicet Bio Research & Development Related Terms

Adicet Bio Research & Development Historical Data

* Premium members only.

The historical data trend for Adicet Bio's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Research & Development Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 43.32 67.26 97.24 94.85 84.65

Adicet Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.10 24.64 19.47 21.38 15.13
FRA:1IJ
31GF Score
Adicet Bio Inc FRA:1IJ
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adicet Bio Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €80.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €80.62 Mil mean?
Adicet Bio (FRA:1IJ) has a Research & Development of €80.62 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Adicet Bio and its competitors.
Is Adicet Bio's Research & Development too high?
Adicet Bio's current Research & Development is €80.62 Mil. Overall, Adicet Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Research & Development compare to EDSA and GOSS?
Adicet Bio's Research & Development of €80.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Adicet Bio and its competitors. Adicet Bio's current Research & Development is €80.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (FRA:1IJ) has a current Research & Development of €80.62 Mil. The current Research & Development is €80.62 Mil. Adicet Bio's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current Research & Development is €80.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adicet Bio Business Description

Other Exchanges ACET:USA0HX7:UK
Address 131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score

Get the complete analysis for FRA:1IJ

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.60
Price